RTC
VIR icon

Riverview Trust Company’s Vir Biotechnology VIR Stock Holding History

Riverview Trust Company’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,586
Closed -$14.9K – 612
2023
Q3 		$14.9K Buy
+1,586
New +$22.6K 0.01% 541

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Riverview Trust Company's VIR Position: Q4 2023 in Review

Riverview Trust Company sold out of Vir Biotechnology (VIR) in Q4 2023, closing a stake of 1,586 shares — an estimated $14.9K sold.

Riverview Trust Company first reported a position in VIR in Q3 2023 and held it in 1 quarter. The position peaked at $14.9K in Q3 2023. 206 funds tracked by Wall St. Rank hold VIR as of Q4 2023.

  • Riverview Trust Company reported no remaining Vir Biotechnology position as of Q4 2023 after selling out during the quarter.
  • Riverview Trust Company sold 1,586 Vir Biotechnology shares in Q4 2023, an estimated $14.9K.
  • Riverview Trust Company first reported a position in Vir Biotechnology in Q3 2023 and held it in 1 quarter.
  • Riverview Trust Company's Vir Biotechnology position peaked at $14.9K in Q3 2023.
  • 206 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2023.

Based on Riverview Trust Company's 13F filing for Q4 2023, filed 24 Jan 2024.